## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims:

Claims 1 to 45. (canceled)

Claim 46. (currently amended) A compound of formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a ( $C_1$ - $C_6$  alkyl) amino group, a di( $C_1$ - $C_6$  alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

 $\mbox{R}^2$  and  $\mbox{R}^3$  are the same or different and represent a hydrogen atom or a  $C_1\text{--}C_6$  alkyl group;

Arom represents an unsubstituted  $\frac{\text{aryl}}{\text{phenyl}}$  group[[, an]]  $\frac{\text{aryl}}{\text{or}}$  or a phenyl group substituted at from 1 to 5 positions by one or more substituents which are the same or different and are from the substituent group  $\alpha$ ; an unsubstituted heteroaryl group[[,]] or a heteroaryl group substituted at from [[1 to 3]] positions by one or more substituents which are the same or different and are from a substituent group  $\alpha$ ;

A represents a  $C_1$ - $C_6$  alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond;

E represents [[a]]  $\frac{\text{single bond}}{\text{single bond}}$  an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a hydrogen atom or a  $C_1-C_7$  alkanoyl group;

 $X^1$  and [[ $X^2$ ]] are the same or different and represent represents an oxygen atom or a sulfur atom;

X² is oxygen and is attached at position C4 of the phenyl
ring;

the substituent group  $\alpha$  being selected from the group consisting of a halogen atom,  $C_1-C_6$  alkyl group, halogeno  $C_1-C_6$ 

alkyl group,  $C_1$ - $C_6$  alkoxy group,  $C_1$ - $C_6$  alkylthio group,  $C_1$ - $C_3$  alkylenedioxy group,  $C_1$ - $C_7$  alkanoyl group,  $C_2$ - $C_7$  alkyloxycarbonyl group, amino group,  $C_1$ - $C_7$  alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group;

or a pharmacologically acceptable salt or ester thereof.

# Claim 47. (currently amended) A compound of formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a  $(C_1$ - $C_6$  alkyl) amino group, a di( $C_1$ - $C_6$  alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

 $\mbox{R}^2$  and  $\mbox{R}^3$  are the same or different and represent a hydrogen atom or a  $\mbox{C}_1\mbox{-}\mbox{C}_6$  alkyl group;

Arom represents an unsubstituted aryl phenyl group[[, an]]

aryl or a phenyl group substituted at from 1 to 5 positions by

one or more substituents which are the same or different and are

from the substituent group  $\alpha$ ; an unsubstituted heteroaryl group [[,]] or a heteroaryl group substituted at from [[1 to 3]] positions by one or more substituents which are the same or different and are from a substituent group  $\alpha$ ;

A represents a  $C_1$ - $C_6$  alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond;

E represents [[a]] single bond[[,]] an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a hydrogen atom or a  $C_1-C_7$  alkanoyl group;

 $X^1$  and [[ $X^2$ ]] are the same or different and represent represents an oxygen atom or a sulfur atom;

 $X^2$  is oxygen and is attached at position C4 of the phenyl ring;

wherein the group of formula  $R^1-C(=X^1)-$  is a  $(C_1-C_4$  alkyl) carbamoyl group or a di $(C_1-C_4$  alkyl) carbamoyl group;

the substituent group  $\alpha$  being selected from the group consisting of a halogen atom,  $C_1$ - $C_6$  alkyl group, halogeno  $C_1$ - $C_6$  alkyl group,  $C_1$ - $C_6$  alkoxy group,  $C_1$ - $C_6$  alkylthio group,  $C_1$ - $C_3$ 

alkylenedioxy group,  $C_1$ - $C_7$  alkanoyl group,  $C_2$ - $C_7$  alkyloxycarbonyl group, amino group,  $C_1$ - $C_7$  alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group;

or a pharmacologically acceptable salt or ester thereof.

# Claim 48. (currently amended) A compound of formula (I):

wherein [[R<sup>1</sup>]] represents a [[C<sub>1</sub>-C<sub>6</sub>]] alkyl group[[,]] an amino-group[[,]] a -([[C<sub>1</sub>-C<sub>6</sub>]] alkyl) amino group [[,]] a di-([[C<sub>1</sub>-C<sub>6</sub>]] alkyl) amino group or a nitrogen[[-]]-containing saturated heterocyclic group[[;]]

 ${\mbox{R}}^2$  and  ${\mbox{R}}^3$  are the same or different and represent a hydrogen atom or a  ${\mbox{C}}_1-{\mbox{C}}_6$  alkyl group;

Arom represents an unsubstituted  $\frac{\text{aryl}}{\text{phenyl}}$  group[[, an]]  $\frac{\text{aryl}}{\text{or a phenyl}}$  group substituted at from 1 to 5 positions by one or more substituents which are the same or different and are from the substituent group  $\alpha$ ; an unsubstituted heteroaryl-

group[[,]] or a heteroaryl group substituted at from [[1 to 3]] positions by one or more substituents which are the same or different and are from a substituent group  $\alpha$ ;

A represents a  $C_1-C_6$  alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond;

E represents [[a]] single bond[[,]] an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a hydrogen atom or a  $C_1-C_7$  alkanoyl group;

[[X<sup>1</sup>]] and [[X<sup>2</sup>]] are the same or different and represent an oxygen atom or a sulfur atom[[;]]

 $X^2$  is oxygen and is attached at position C4 of the phenyl ring;

wherein the group of formula  $R^1-C(=X^1)$  - is a dimethylcarbamoyl group or an ethylmethylcarbamoyl group;

the substituent group  $\alpha$  being selected from the group consisting of a halogen atom,  $C_1$ - $C_6$  alkyl group, halogeno  $C_1$ - $C_6$  alkyl group,  $C_1$ - $C_6$  alkoxy group,  $C_1$ - $C_6$  alkylthio group,  $C_1$ - $C_3$  alkylenedioxy group,  $C_1$ - $C_7$  alkanoyl group,  $C_2$ - $C_7$  alkyloxycarbonyl

group, amino group,  $C_1$ - $C_7$  alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group; or a pharmacologically acceptable salt or ester thereof.

# Claim 49. (currently amended) A compound of formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a  $(C_1$ - $C_6$  alkyl) amino group, a di( $C_1$ - $C_6$  alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

 $\mbox{R}^2$  and  $\mbox{R}^3$  are the same or different and represent a hydrogen atom or a  $\mbox{C}_1\mbox{-}\mbox{C}_6$  alkyl group;

Arom is a phenyl group substituted at one or two positions by one or more substituents which are the same or different and are from a substituent group  $\alpha l$ , or a phenyl group substituted at three positions by halogen atoms;

A represents a  $C_1$ - $C_6$  alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond;

E represents [[a]] single bond[[,]] an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a hydrogen atom or a  $C_1-C_7$  alkanoyl group;

 $X^1$  [[and  $X^2$ ]] are the same or different and represent represents an oxygen atom or a sulfur atom;

 $\underline{X^2}$  is oxygen and is attached at position C4 of the phenyl ring;

the substituent group  $\alpha l$  being selected from the group consisting of a halogen atom, unsubstituted  $C_1$ - $C_4$  alkyl group,  $C_1$ - $C_4$  alkyl group substituted by from 1 to 3 fluorine atoms,  $C_1$ - $C_4$  alkoxy group,  $C_1$ - $C_4$  alkylthio group, methylenedioxy group, ethylenedioxy group,  $C_1$ - $C_4$  alkanoyl group, cyano group and nitro group;

or a pharmacologically acceptable salt or ester thereof.

# Claim 50. (currently amended) A compound of formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a  $(C_1$ - $C_6$  alkyl) amino group, a di( $C_1$ - $C_6$  alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

 $\mbox{R}^2$  and  $\mbox{R}^3$  are the same or different and represent a hydrogen atom or a  $\mbox{C}_1\mbox{-}\mbox{C}_6$  alkyl group;

Arom is a phenyl group substituted at one or two positions by one or more substituents which are the same or different and are from a substituent group  $\alpha 3$ , or a phenyl group substituted at three positions by fluorine atoms;

A represents a C<sub>1</sub>-C<sub>6</sub> alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond;

E represents [[a]] single bond[[,]] an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a hydrogen atom or a  $C_1-C_7$  alkanoyl group;

 $X^1$  and [[ $X^2$ ]] are the same or different and represent represents an oxygen atom or a sulfur atom;

 $X^2$  is oxygen and is attached at position C4 of the phenyl ring;

the substituent group  $\alpha 3$  being selected from the group consisting of a fluorine atom, chlorine atom, methylthio group, acetyl group, cyano group and nitro group;

or a pharmacologically acceptable salt or ester thereof.

Claim 51. (previously presented) A compound of formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a  $(C_1$ - $C_6$  alkyl) amino group, a di( $C_1$ - $C_6$  alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

 $\mbox{R}^2$  and  $\mbox{R}^3$  are the same or different and represent a hydrogen atom or a  $\mbox{C}_1\mbox{-}\mbox{C}_6$  alkyl group;

Arom is a phenyl group substituted at one position by a fluorine atom, a chlorine atomor a nitro group, or a phenyl group substituted at two positions by fluorine atoms;

A represents a  $C_1$ - $C_6$  alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond;

E represents [[a]] single—bond[[,]] an oxygen atom, a sulfur atom or a group of the formula  $-NR^4$ -, wherein  $R^4$  represents a hydrogen atom or a  $C_1$ - $C_7$  alkanoyl group;

 $X^1$  and [[ $X^2$ ]] are the same or different and represent represents an oxygen atom or a sulfur atom;

 $X^2$  is oxygen and is attached at position C4 of the phenyl ring;

or a pharmacologically acceptable salt or ester thereof.

# Claim 52. (previously presented) A compound of formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a  $(C_1$ - $C_6$  alkyl) amino group, a di( $C_1$ - $C_6$  alkyl) amino group or a nitrogen-containing saturated heterocyclic group;

 $\mbox{R}^2$  and  $\mbox{R}^3$  are the same or different and represent a hydrogen atom or a  $\mbox{C}_1\mbox{-}\mbox{C}_6$  alkyl group;

Arom is a 4-fluorophenyl group, a 4-chlorophenyl group, a 4-nitrophenyl group or a 3,4-difluorophenyl group;

A represents a  $C_1-C_6$  alkylene group;

 $R^a$  represents a hydrogen atom, a  $C_1$ - $C_6$  alkyl group or a  $C_2$ - $C_6$  alkenyl group [[or,]] together with [[ $R^2$ ,]] represents a [[ $C_1$ - $C_3$ ]] alkylene group without a double bond or a [[ $C_2$ - $C_3$ ]] alkylene group with a double bond[[;]]

E represents [[a]]  $\frac{1}{1}$  single  $\frac{1}{1}$  an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a

Appl. No. 10/629,108
Response to Office Action mailed January 3, 2006

hydrogen atom or a C<sub>1</sub>-C<sub>7</sub> alkanoyl group;

X<sup>1</sup> and [[X<sup>2</sup>]] are the same or different and represent represents an oxygen atom or a sulfur atom;

 $X^2$  is oxygen and is attached at position C4 of the phenyl ring;

or a pharmacologically acceptable salt or ester thereof.

Claim 53. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula:  $R^1-C$  (= $X^1$ ) - is a carbamoyl group, a ( $C_1-C_4$  alkyl) carbamoyl group, a di( $C_1-C_4$  alkyl) carbamoyl group, a thiocarbamoyl group, a ( $C_1-C_4$  alkyl) thiocarbamoyl group or a di( $C_1-C_4$  alkyl) thiocarbamoyl group.

Claim 54. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula  $R^1-C(=X^1)$  is a  $(C_1-C_4$  alkyl) carbamoyl group, a  $di(C_1-C_4$  alkyl) carbamoyl group, a  $(C_1-C_4$  alkyl) thiocarbamoyl group or a  $di(C_1-C_4$  alkyl) thiocarbamoyl group.

Claim 55. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46,  $\dot{4}9$ , 50, 51 or 52, wherein the group of formula  $R^1-C(=X^1)$  is a di( $C_1-C_4$  alkyl)carbamoyl group.

Claim 56. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein the group of formula  $R^1-C(=X^1)$  is a dimethylcarbamoyl group.

Claim 57. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein  $\mathbb{R}^3$  is a  $\mathbb{C}_{1}$ - $\mathbb{C}_{6}$  alkyl group.

Claim 58. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein  $\mathbb{R}^3$  is a methyl group or an ethyl group.

Claim 59. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to

any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein  $\mathbb{R}^3$  is a methyl group.

Claim 60. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein  $\mathbb{R}^2$  is a hydrogen atom or a  $\mathbb{C}_1$ - $\mathbb{C}_6$  alkyl group.

Claim 61. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein  $\mathbb{R}^2$  is a hydrogen atom, a methyl group or an ethyl group.

Claim 62. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein  $\mathbb{R}^2$  is a hydrogen atom or a methyl group.

## Claim 63. (canceled)

#### Claim 64. (canceled)

### Claim 65. (canceled)

Claim 66. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein R<sup>a</sup> is a hydrogen atom or a methyl group.

Claim 67. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein R<sup>a</sup> is a hydrogen atom.

Claim 68. (currently amended) The compound or pharmacologically acceptable salt or ester thereof according to Claims 46 or 47, wherein Arom is an unsubstituted phenyl group [[,]] a phenyl group substituted at from 1 to 3 positions by one or more substituents which are the same or different and are from the substituent group  $\alpha$ , an unsubstituted pyridyl group [[,]] or a pyridyl group substituted at one position by a substituent from the substituent group [[ $\alpha$ ]],

the substituent group  $\alpha$  being selected from the group consisting of a halogen atom,  $C_1$ - $C_6$  alkyl group, halogeno  $C_1$ - $C_6$  alkyl group,  $C_1$ - $C_6$  alkoxy group,  $C_1$ - $C_6$  alkylthio group,  $C_1$ - $C_3$  alkylenedioxy group,  $C_1$ - $C_7$  alkanoyl group,  $C_2$ - $C_7$  alkyloxycarbonyl group, amino group,  $C_1$ - $C_7$  alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group.

#### Claim 69. (canceled)

Claim 70. (previously presented) The compound or pharmacologically acceptable salt thereof according to Claims 46 or 47, wherein Arom is a phenyl group substituted at one or two positions by substituent(s) which are the same or different and are from a substituent group  $\alpha 2$ , or a phenyl group substituted at three positions by fluorine atoms or chlorine atoms; substituent group  $\alpha 2$  being selected from the group consisting of a fluorine atom, chlorine atom, methyl group, trifluoromethyl group, methoxy group, methylthio group, acetyl group, cyano group and nitro group.

Claim 71. (previously presented) The compound or pharmacologically acceptable salt thereof according to Claims 46

or 47, wherein Arom is a phenyl group substituted at one or two positions by one or more substituents which are the same or different and are from a substituent group  $\alpha 4$ , or a phenyl group substituted at three positions by fluorine atoms; substituted group  $\alpha 4$  being selected from the group consisting of a fluorine atom, chlorine atom, methylthio group and nitro group.

Claim 72. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein A is a  $C_1$ - $C_4$  alkylene group.

Claim 73. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein A is a methylene group or an ethylene group.

Claim 74. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein A is an ethylene group.

Appl. No. 10/629,108
Response to Office Action mailed January 3, 2006

# Claim 75. (canceled)

Claim 76. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein E is an oxygen atom.

## Claim 77. (canceled)

Claim 78. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 47, 48, 49, 50, 51 or 52, wherein the group of formula  $R^1$ - $C(=X^1)-X^2$ - is attached at the para-position.

Claim 79. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein  $R^1$  is an amino group, a  $(C_1-C_6$  alkyl)amino group or a di $(C_1-C_6$  alkyl)amino group.

Claim 80. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein  $R^1$  is an amino group, a  $(C_1-C_4$  alkyl)amino group or a  $di(C_1-C_4$  alkyl)amino group.

Claim 81. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein  $R^1$  is a  $(C_1-C_4$  alkyl)amino group or a di $(C_1-C_4$  alkyl)amino group.

Claim 82. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to any one of Claims 46, 49, 50, 51 or 52, wherein  $X^1$  is an oxygen atom.

Claim 83. (currently amended) The compound or pharmacologically acceptable salt or ester thereof according to Claim 46, wherein the compound is 4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethcarbamate dimethylcarbamate.

# Claim 84. (currently amended) A compound of the formula (I):

wherein  $R^1$  represents a  $C_1$ - $C_6$  alkyl group, an amino group, a  $(C_1$ - $C_6$  alkyl)amino group, a di( $C_1$ - $C_6$  alkyl)amino group or a nitrogencontaining saturated heterocyclic group;

Ġ.

 $R^2$  and  $R^3$  are the same or different and represent a hydrogen atom or a  $C_1$ - $C_6$  alkyl group;

Arom represents an unsubstituted  $\frac{\alpha}{\alpha}$  phenyl group[[, an]]  $\frac{\alpha}{\alpha}$  or a phenyl group substituted at from 1 to 3 positions by substituents, which are the same or different and are from a substituent group  $\alpha$ ; an unsubstituted heteroaryl group[[,]] or a heteroaryl group substituted at from 1 to 3 positions by one or more substituents which are the same or different and are from a substituent group  $\alpha$ [[;]]

A represents a  $C_1$ - $C_6$  alkylene group;

E represents [[a]] single bond[[,]] an oxygen atom, a sulfur atom or a group of the formula  $-NR^4-$ , wherein  $R^4$  represents a hydrogen atom or a  $C_1-C_7$  alkanoyl group;

 $X^1$  and [[ $X^2$ ]] are the same or different and represent represents an oxygen atom or a sulfur atom;

 $\underline{X^2}$  is oxygen and is attached at position C4 of the phenyl ring;

the substituent group  $\alpha$  being selected from the group consisting of a halogen atom,  $C_1$ - $C_6$  alkyl group, halogeno  $C_1$ - $C_6$  alkyl group,  $C_1$ - $C_6$  alkoxy group,  $C_1$ - $C_6$  alkylthio group,  $C_1$ - $C_3$  alkylenedioxy group,  $C_1$ - $C_7$  alkanoyl group,  $C_2$ - $C_7$  alkyloxycarbonyl group, amino group,  $C_1$ - $C_7$  alkanoylamino group, hydroxyl group, mercapto group, cyano group, nitro group and carboxyl group; or a pharmacologically acceptable salt or ester thereof.

Claim 85. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 46, in combination with a pharmaceutically acceptable carrier.

Claim 86. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 47, in combination with a pharmaceutically acceptable carrier.

Claim 87. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 48, in combination with a pharmaceutically acceptable carrier.

Claim 88. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 49, in combination with a pharmaceutically acceptable carrier.

Claim 89. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 50, in combination with a pharmaceutically acceptable carrier.

Claim 90. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to

Claim 51, in combination with a pharmaceutically acceptable carrier.

Claim 91. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 52, in combination with a pharmaceutically acceptable carrier.

Claim 92. (previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 83, in combination with a pharmaceutically acceptable carrier.

#### Claims 93 to 101. (canceled)

Claim 102. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a mammal comprising administering to a mammal a pharmaceutically effective

amount of a compound or a pharmacologically acceptable salt or ester thereof according to Claim 46.

Claim 103. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 46.

Claim 104. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 47.

Claim 105. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically

effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 48.

Claim 106. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 49.

Claim 107. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 50.

Claim 108. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically

effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 51.

Claim 109. (previously presented) A method for treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 52.

## Claim 110. (canceled)

Claim 111. (previously presented) A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 46.

Claim 112. (previously presented) A method for treating

Alzheimer's disease in a human comprising administering to said

human a pharmaceutically effective amount of a compound or

pharmacologically acceptable salt or ester thereof according to Claim 47.

Claim 113. (previously presented) A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 48.

Claim 114. (previously presented) A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 49.

Claim 115. (previously presented) A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 50.

Claim 116. (previously presented) A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 51.

Claim 117. (previously presented) A method for treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically effective amount of a compound or pharmacologically acceptable salt or ester thereof according to Claim 52.

## Claim 118. (canceled)

Claim 119. (previously presented) The compound or pharmacologically acceptable salt or ester thereof according to Claim 46, wherein  $R^1$  is a dimethylamino group,  $X^1$  and  $X^2$  are both oxygen, Ra is H,  $R^2$  is hydrogen,  $R^3$  is methyl, A is  $-C_2H_4$ , E is oxygen and Arom is a phenyl group substituted in the 4-position by a  $NO_2$  group.

- Claim 120. (new) The compound according to claim 46, wherein the compound is selected from the group consisting of
- 4-[3-(4-fluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(3-fluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(4-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(3-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(3,4-difluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(4-chloro-3-fluorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(2-chloro-4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-[1-dimethylamino-3-(4-fluorophenoxy)propyl]phenyl dimethylcarbamate,
- 4-[1-dimethylamino-3-(3-fluorophenoxy)propyl]phenyl dimethylcarbamate,
- 4-[3-(4-chlorophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(3-chlorophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,

- 4-[3-(4-cyanophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
- 4-[1-dimethylamino-3-(4-nitrophenoxy)propyl]phenyl dimethylcarbamate,
- 4-[3-(3,4-difluorophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(2-chloro-4-nitrophenoxy)-1-dimethylaminopropyl]phenyl dimethylcarbamate,
- 4-[3-(4-nitrophenylsulfanyl)-1-methylaminopropyl]phenyl dimethylcarbamate,
- 4-(1-methylamino-3-p-toluyloxypropyl)phenyl dimethylcarbamate hydrochloride,
- 4-[1-methylamino-3-[(4-trifluoromethyl)phenoxy]propyl]phenyl dimethylcarbamate,
- 4-[3-(4-cyanophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate and
- 4-[1-methylamino-3-(3-nitrophenoxy)propyl]phenyl dimethylcarbamate
- or a pharmacologically acceptable salt or ester thereof.
- Claim 121. (new) The compound according to claim 46, wherein the compound is 4-[3-(4-chlorophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate or a pharmacologically acceptable salt or ester thereof.
- Claim 122. (new) The compound according to claim 46, wherein the compound is (S)-4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate or a pharmacologically acceptable salt or ester thereof.

- Claim 123. (new) The compound according to claim 46, wherein the compound is (S)-4-[3-(4-chlorophenoxy)-1-methylaminopropyl] phenyl dimethylcarbamate or a pharmacologically acceptable salt or ester thereof.
- Claim 124. (new) The compound according to claim 46, wherein the compound is (S)-4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate hydrochloride.
- Claim 125. (new) The compound according to claim 46, wherein the compound is (S)-4-[3-(4-chlorophenoxy)-1-methylaminopropyl] phenyl dimethylcarbamate hydrochloride.
- Claim 126. (new) The compound according to claim 46, wherein the compound is (S)-4-[3-(4-nitrophenoxy)-1-methylaminopropyl]phenyl dimethylcarbamate hemifumarate.
- Claim 127. (new) The compound according to claim 46, wherein the compound is (S)-4-[3-(4-chlorophenoxy)-1-methylaminopropyl] phenyl dimethylcarbamate hemifumarate.
- Claim 128. (new) A method of treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically acceptable amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 83, 121, 122 or 123.

- Claim 129. (new) A method of treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically acceptable amount of a compound according to any one of claims 124, 125, 126 or 127.
- Claim 130. (new) A method of treating depression, Huntington's chorea, Pick's disease, tardive dyskinesia, a compulsive disorder or a panic disorder in a human comprising administering to said human a pharmaceutically acceptable amount of a compound according to claim 126.
- Claim 131. (new) A method of treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically acceptable amount of a compound or pharmaceutically acceptable salt thereof according to any one of claims 83, 121, 122 or 123.
- Claim 132. (new) A method of treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically acceptable amount of a compound according to any one of claims 124, 125, 126 or 127.
- Claim 133. (new) A method of treating Alzheimer's disease in a human comprising administering to said human a pharmaceutically acceptable amount of a compound or pharmaceutically acceptable salt thereof according to claim 126.